Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Recruiting 4Completed 1Active not recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Head & Neck 6

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 9Neoplasms 8Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Recurrence 4Esophageal Squamous Cell Carcinoma 4Colonic Neoplasms 4Stomach Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Solid Cancers 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2EBV-associated Tumors 2Cholangiocarcinoma 2Breast Neoplasms 2Bites and Stings 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2

Interventions

Cisplatin 32Gemcitabine 21Radiotherapy, Intensity-Modulated 16toripalimab 14Capecitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiotherapy 7Drug Therapy 7pembrolizumab 6Platinum 6Nivolumab 6Immune Checkpoint Inhibitors 61,2-diaminocyclohexaneplatinum II citrate 6Docetaxel 5tislelizumab 4spartalizumab 4camrelizumab 4sintilimab 3anlotinib 3Immunoglobulin G 3Disulfides 3Carboplatin 3nimotuzumab 2fludarabine 2atezolizumab 2Taxes 2Radiation 2Phantoms, Imaging 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Immune Checkpoint Inhibitors × 1 year × Clear all
NCT07590024 2026-06-04

RAIRI-NPC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3 Recruiting
651 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT07618078 2026-06-03

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting
900 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05941741 2026-05-11

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Sun Yat-sen University

Phase 3 Recruiting
380 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Sun Yat-sen University

Phase 2 Recruiting
208 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT03984357 2025-07-17

PLATINUM

Sun Yat-sen University

Phase 2 Completed
152 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04907370 2025-07-16

DIAMOND

Sun Yat-sen University

Phase 3 Active not recruiting
532 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡